Real-World Evidence of Temporal Variation in PD-L1 Expression

被引：0
|
作者：
Sudarsanam, Sucha [1 ]
Hatooglu, Medina [1 ]
O'Malley, Dennis [2 ]
Weiss, Lawrence [3 ]
机构：
[1] NeoGen Labs Inc, Aliso Viejo, CA USA
[2] NeoGen Labs Inc, Dana Point, CA USA
[3] NeoGen Labs Inc, Pasadena, CA USA
来源：
MODERN PATHOLOGY | 2020年 / 33卷 / SUPPL 2期
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
1830
引用
收藏
页码：1713 / 1714
页数：2
相关论文
共 50 条
  • [21] Pembrolizumab monotherapy in advanced NSCLC patients with low PD-L1 expression: is there real evidence?
    Fiorelli, Alfonso
    Vitiello, Fabiana
    Morgillo, Floriana
    Santagata, Mario
    Spuntarelli, Chiara
    Di Domenico, Marina
    Santini, Mario
    Bianco, Andrea
    TRANSLATIONAL CANCER RESEARCH, 2019, 8 : S618 - S620
  • [22] Correlation between FGFR mutation and PD-L1 expression of urinary bladder cancers: A real-world based biomarker study.
    Maraz, Aniko
    Takacs, Peter
    Lawson, Joe
    Santiago-Walker, Ademi
    Pajor, Laszlo
    Sukosd, Farkas
    Revesz, Janos
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [23] PD-L1 expression affect the efficacy of pemetrexed maintenance therapy in real-world patients with advanced non-squamous NSCLC
    Qin, Y.
    Jiang, L.
    Li, Y.
    Ren, L.
    Wang, Y.
    Gong, Y.
    Peng, F.
    Zhu, J.
    Ding, Z.
    Liu, Y.
    Yu, M.
    Lu, Y.
    Huang, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [24] Real-World Prevalence of PD-L1 Expression in Advanced NoneSmall-Cell Lung Cancer: The Global, Multicenter EXPRESS Study
    Salanova, R.
    Dietel, M.
    Savelov, N.
    Micke, P.
    Bigras, G.
    Hida, T.
    Piperdi, B.
    Burke, T.
    Khambata-Ford, S.
    Deitz, A.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : S155 - S156
  • [25] Comparative analysis of PD-L1 expression and molecular alterations in primary versus metastatic lung adenocarcinoma: a real-world study in China
    Chen, Gang
    Yu, Yang
    Qi, Youchao
    Li, Guangxu
    Li, Ning
    Meng, Fande
    Wang, Wujie
    Shen, Rong
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [26] Real-world PD-L1 testing and distribution of PD-L1 tumor expression by immunohistochemistry assay type among patients with metastatic non-small cell lung cancer in the United States
    Velcheti, Vamsidhar
    Patwardhan, Pallavi D.
    Liu, Frank Xiaoqing
    Chen, Xin
    Cao, Xiting
    Burke, Thomas
    PLOS ONE, 2018, 13 (11):
  • [27] Real-World Comparative Effectiveness in Advanced NSCLC and High PD-L1 with 1L Immune Checkpoint Inhibitors ± Chemotherapy
    Hsu, M. L.
    Xia, Q.
    Aggarwal, S.
    Nkhoma, E.
    R, D.
    Hager, T.
    Quek, R.
    Feliciano, J.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S598 - S598
  • [28] PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer
    Monneur, Audrey
    Goncalves, Anthony
    Bertucci, Francois
    BULLETIN DU CANCER, 2018, 105 (03) : 261 - 272
  • [29] Author Correction: Real-world evidence and clinical observations of the treatment of advanced non-small cell lung cancer with PD-1/PD-L1 inhibitors
    Peng Song
    Jingcheng Zhang
    Congcong Shang
    Li Zhang
    Scientific Reports, 10
  • [30] PD-L1 inhibitors combined with whole brain radiotherapy in patients with small cell lung cancer brain metastases: Real-world evidence
    Huang, Litang
    Chen, Shen
    Liu, Hui
    Meng, Lu
    Liu, Chengxing
    Wu, Xiaoting
    Wang, Yingying
    Luo, Shilan
    Tu, Hongbin
    Wang, Chunlei
    Zhang, Ming
    Gong, Xiaomei
    CANCER MEDICINE, 2024, 13 (07):
12345